Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EU Agencies Consider Phenylbutazone Detected in Horsemeat of Low Concern for Consumers

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
Agencies recommend improved horse traceability and monitoring of veterinary medicinal residues.

A joint assessment from the European Food Safety Authority (EFSA) and the European Medicines Agency (EMA) concludes that the illegal presence of residues of phenylbutazone in horsemeat is of low concern for consumers due to the low likelihood of exposure and the overall low likelihood of toxic effects. EFSA and EMA confirm that it is not possible to set safe levels for phenylbutazone in food products of animal origin and therefore its use in the food chain should remain prohibited.

As part of this remit, EFSA and EMA delivered a series of recommendations to further reduce the risk of this substance entering the food chain, focusing on measures to strengthen traceability. The agencies reiterate the need to improve the monitoring and reporting of data on the presence of residues of veterinary medicines in live animals and food products of animal origin across the European Union (EU).

The request for advice from the European Commission follows the recent identification of beef products adulterated with horsemeat and the discovery of the anti-inflammatory drug phenylbutazone in horse carcasses illegally entering the food chain.

Phenylbutazone was previously evaluated by EMA in 1997 to establish maximum residue limits (MRLs) in food products of animal origin. The data available at that time did not allow a conclusion to be drawn on the level of phenylbutazone that could be considered safe in food of animal origin. As no MRL could be established, animals treated with phenylbutazone are not allowed to enter the food chain. In their joint risk assessment, experts from EFSA and EMA used all currently available scientific evidence to assess the toxicity of phenylbutazone and reconfirmed these conclusions.

EFSA and EMA identified the health hazards associated with phenylbutazone and assessed whether consumer exposure to this substance through its illegal presence in horsemeat could be of concern.

Phenylbutazone is occasionally used in human medicine for the treatment of patients with severe rheumatoid arthritis and has been linked to rare occurrence of a blood disorder, aplastic anemia, which has been observed in 1 in 30,000 people treated. The report concluded that the likelihood that a predisposed individual consume horsemeat contaminated with the drug and develop this condition is low – between 2 in a trillion and 1 in 100 million.This estimate takes into account the likelihood of consumers being exposed to phenylbutazone on a given day from the consumption of horsemeat itself or from beef products adulterated with horsemeat.

EFSA and EMA found that while the genotoxicity of phenylbutazone (that is, its potential to damage human DNA) could not be excluded, this was considered unlikely.The report also concluded that the risk of carcinogenicity is of very low concern given the estimated infrequency of consuming horsemeat containing residues ofphenylbutazone (consumed as such or in beef products adulterated with horsemeat) and the estimated low levels of the drug to which consumers could be exposed through the diet. In estimating possible levels of phenylbutazone in foods, scientists used the highest concentration of the drug reported in the testing programme carried out by Member States.

Traceability and monitoring

EFSA and EMA provided advice to further reduce the risk to consumers from the illegal presence of phenylbutazone in horsemeat. Proposed EU-wide measures include introduction of a reliable identification system for horses and other so-called solipeds, harmonising checks of phenylbutazone and improving the reporting of monitoring data for its possible presence in foods. This final suggestion echoes a recommendation made by EFSA in its latest report on Veterinary Medicines Residues.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EU Drug Regulator Recommends 1st License for Malaria Shot
Mosquirix to be used for vaccination of young children, together with established antimalarial interventions.
Monday, July 27, 2015
First Stem-Cell Therapy Recommended For Approval In EU
New treatment for rare condition caused by burns to the eye.
Monday, December 22, 2014
European Medicines Agency Launches Adaptive Licensing Pilot Project
Improving timely access for patients to new medicines: pilot explores adaptive licensing approach with real medicines in development.
Friday, March 21, 2014
Investigation Into GLP-1 Based Diabetes Therapies Concluded
No new concerns for GLP-1 therapies identified on the basis of available evidence.
Friday, July 26, 2013
European Medicines Agency Recommends Changes to the Use of metoclopramide
Changes aim mainly to reduce the risk of neurological side effects.
Friday, July 26, 2013
European Medicines Agency Reorganisation
Re-shaping a regulatory agency fit for the future.
Friday, May 03, 2013
Meeting highlights from the Pharmacovigilance Risk Assessment Committee
Outcome of periodic safety update report assessment leads to recommendation to restrict use of a medicine.
Monday, April 15, 2013
European Medicines Agency Gives First Opinion for a Vaccine for Use Outside the EU
New vaccine offers protection against six WHO priority diseases.
Monday, June 25, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!